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NetherlandsA B S T R A C TObjectives: To develop a mapping algorithm for estimating EuroQol
ﬁve-dimensional (EQ-5D) questionnaire values from the prostate
cancer–speciﬁc health-related quality-of-life (HRQOL) instrument
Functional Assessment of Cancer Therapy–Prostate (FACT-P) instru-
ment. Methods: The EQ-5D questionnaire and FACT-P instrument
data were collected for a subset of patients with metastatic castration-
resistant prostate cancer in a multicenter, randomized, double-blind,
placebo-controlled phase 3 trial. We compared three statistical tech-
niques to estimate patients’ EQ-5D questionnaire index scores deter-
mined by using the UK tariff: 1) generalized estimating equations, 2)
two-part model combining logistic regression and generalized esti-
mating equation, and 3) separate mapping algorithms for patients
with poor health deﬁned as a FACT-P score of 76 or less (group-speciﬁc
model). Four different sets of explanatory variables were compared.
The models were cross-validated by using a 10-fold in-sample cross-
validation. Results: Values for both instruments were available forsee front matter Copyright & 2014, International S
r Inc.
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ndence to: Konstantina Skaltsa, C/Sardenya 537 Ba236 patients with metastatic castration-resistant prostate cancer. The
group-speciﬁc model including the FACT-P subscale scores and base-
line variables had the best predictive performance with R2 0.718, root
mean square error 0.162, and mean absolute error 0.117. The two-part
model and the generalized estimating equation model including the
FACT-P subdomain scores and baseline variables also had good
predictive performance. Conclusions: The developed algorithms for
mapping the FACT-P instrument to the EQ-5D questionnaire enable
the estimation of preference-based health-related quality-of-life
scores for use in cost-effectiveness analyses when directly elicited
EQ-5D questionnaire data are missing.
Keywords: EQ-5D, FACT-P, mapping, metastatic castration-resistant
prostate cancer, quality of life.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Data on health-related quality of life (HRQOL) measures, such as
the Functional Assessment of Cancer Therapy–Prostate (FACT-P),
are routinely collected in oncology studies. These HRQOL tools do
not provide preference-based scores, which are crucial for devel-
oping cost-utility models used to inform health-related resource
allocation. The National Institute for Health and Care Excellence
(NICE) in England and Wales states that its preferred measure of
outcome for economic evaluation is the quality-adjusted life-
year, and the EuroQol ﬁve-dimensional (EQ-5D) questionnaire is
the preferred measure of health-related utility required to incor-
porate the quality-of-life element [1]. In the absence of
preference-based scores, such as those derived from the EQ-5D
questionnaire, a statistical model can be estimated that “maps”
the HRQOL measures to utility values.
Mapping functions have been developed for multiple HRQOL
instruments in different areas, such as cancer [2–5], HIV [6],
cardiology [7], arthritis [8], and ophthalmology [9]. There arecurrently no “standard” models for mapping, and different
statistical techniques have been used to take account of the
nature of EQ-5D questionnaire utility data, that is, negatively
skewed and with an upper bound at value 1 representing full
health, the most usual being linear regression using ordinary
least squares (OLS). Although it is widely recognized that the
EQ-5D questionnaire distribution violates the OLS regression
assumptions of normality of the residual distribution and homo-
scedasticity, most studies that have compared alternative models
concluded that the OLS gives the best overall performance in
terms of indexes, such as R2 and root mean square error (RMSE).
Methods that have been used to reﬂect the skewed distribution of
the data or the upper bound include Tobit and median regression
[2], with the most common model being the censored least
absolute deviation [4,5]. Other approaches dealing with the
common multimodal distribution of the data were two-part
models (TPMs) and latent class models and in a more general
form, mixture models [6,10]. Pullenayegum et al. [11,12] advise
against Tobit and censored least absolute deviation models andociety for Pharmacoeconomics and Outcomes Research (ISPOR).
jos, 08024 Barcelona, Spain.
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and latent class models if data are bimodal. Nonetheless, most
published mapping studies have used cross-sectional designs
and prediction models were derived from baseline data. Only a
few studies have used repeatedly measured data; for example,
Bansback et al. [8] used generalized estimating equations (GEEs)
and Hernández Alava et al. [13] used an adjusted censored
mixture model. This may be due to such data frequently being
unavailable for the purpose of mapping; however, as such data
become available, the need for appropriate analytical methods
becomes increasingly important [14]. Other mapping approaches
have attempted to map to the dimension level of the EQ-5D
questionnaire and then apply the relevant tariff of utility values
[15,16]. In the absence of patient-level data, authors have also
investigated mapping the mean non–preference-based scores to
mean utility values, instead of subject-speciﬁc estimation [17].
The objective of the present article was to develop a reliable
mapping algorithm to estimate EQ-5D questionnaire index values
from the FACT-P instrument for use in cost-effectiveness analyses.Methods
Study Sample and Instruments
Data from a multicenter, randomized, double-blind, placebo-
controlled phase 3 trial in patients with metastatic castration-
resistant prostate cancer (mCRPC) were used in this analysis. The
study was conducted at 156 sites in 15 countries, and patients
were enrolled from September 2009 through November 2010.
Details on the study design and the inclusion/exclusion criteria
are described elsewhere [18].
HRQOL was measured by the preference-based EQ-5D ques-
tionnaire and the non–preference-based FACT-P instrument.
Data on both instruments were collected at baseline visit and
follow-up visits at week 13, 25, and every subsequent 12 weeks.
The collection of EQ-5D questionnaire data was instituted at all
sites in France, Germany, Italy, Spain, and the United Kingdom
via an amendment to the protocol. Therefore, only those patients
who were randomized after the Central Ethics Committee appro-
val date qualiﬁed for the EQ-5D questionnaire data collection.
Information on patients’ demographic characteristics, treatment
history, and extent of disease was collected at baseline. More-
over, a pain diary was collected 1 week before baseline and an
assessment on the fatigue severity took place at baseline accord-
ing to the National Cancer Institute Common Terminology
Criteria for Adverse Events 4.0 criteria. Both arms of the trial
were combined for the analysis presented here.
The FACT-P instrument (version 4) is a multidimensional,
self-administered 39-item questionnaire composed of the FACT-
General (FACT-G) original subscales, a general HRQOL instrument
intended for patients with chronic illnesses, and a prostate
cancer subscale (PCS) [19]. The FACT-G subscales are Physical
Well-being (PWB), Social/Family Well-being (SWB), Emotional
Well-being (EWB), and Functional Well-being (FWB). Each item
is rated on a ﬁve-point Likert scale ranging from 0 (not at all) to 4
(very much) and a subscale as well as a total score calculated as
the sum of the items comprising it after some items being
reversed. The theoretical range of these scores is (0–156) for the
FACT-P total score, (0–108) for the FACT-G total score, (0–28) for
the PWB, SWB, and FWB, (0–24) for EWB, and (0–48) for PCS. A
higher score indicates better quality of life.
The EQ-5D questionnaire has been designed as an interna-
tional, standardized, generic instrument for describing and valu-
ing HRQOL [20]. The EQ-5D questionnaire descriptive system
includes ﬁve dimensions of health—mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression—with onequestion per domain. In the version used for this study, there
are three levels of response, corresponding to increasing levels of
impairment: no problems, some/moderate problems, and unable
to/extreme problems. An EQ-5D questionnaire health state utility
index is provided for each of the health states described by the
instrument based on values provided in large general population
studies. In this study, the UK preference weights have been
applied [21].
Methodology
Utility index values were treated as continuous variables. Three
approaches were used to build prediction models described in
detail in the following sections.
Generalized estimating equations
Because of the longitudinal nature of the study, observations
from each instrument between visits are expected to be corre-
lated. The GEE method was chosen as an adequate framework
that allows for the longitudinal nature of the study to be taken
into account and the covariance structure to be built. Two main
types of models were considered: one with the FACT-P instru-
ment total score as a covariate and the other one introducing the
ﬁve domains scores of the FACT-P instrument. Patient and
disease characteristics were also included in the prediction
models: age, weight, Eastern Cooperative Oncology Group per-
formance at baseline (0–1 or 2), previous chemotherapy regimens
(1 orZ2), pain average score (o4 orZ4), and fatigue severity (0 or
Z1). These were the main variables of interest and are typically
collected in prostate cancer studies. Furthermore, it was expected
that these variables would potentially have an effect on the EQ-
5D questionnaire scores during the study. Variables were selected
by using a backwards stepwise selection procedure removing
variables that were not signiﬁcant at the 0.05 level. We have not
considered any interactions. A review of studies mapping (or
cross walking) non–preference-based measures of health to
generic preference-based measures revealed that moving from
total or dimension to item-level models or adding interactions
and other terms had quite modest and negligible improvements
[22]. Increasing complexity in this way only rarely had a major
effect on the range of scores being predicted and goodness of ﬁt
and was therefore not included in this analysis.
Two-part model
The EQ-5D questionnaire with UK weights takes values between
0.594 and 1. It is common to have a ceiling effect for higher values,
that is, a high proportion of patients with value 1 indicating full
health, which was also observed in our data (see left panel of Fig. 1,
histogram of observed EQ-5D questionnaire values). To reﬂect the
ceiling effect in the data, we considered a TPM that consists of
modeling the probability of attaining the upper bound (i.e., 1), and
then model the remainder of the distribution below this bound. The
probability of attaining a utility value of 1 was estimated by using a
generalized logistic regression model, and the rest of the data, that
is, utility less than 1, were accommodated by using a GEE model.
The ﬁnal predicted utility was calculated as a weighted sum of the
probabilities of the two parts as follows: P(utility ¼ 1)  1 þ P(utility
o1)  predicted utility from the GEE model.
Group-speciﬁc model
We also evaluated the performance of ﬁtting two different GEE
models in two subsets of the data following the concerns of
Kontodimopoulos et al. [14]. On the basis of the methodology
presented in Versteegh et al. [23] to correct for the tendency of
these models to overpredict in patients with poor health, we
identiﬁed patients in poor health by FACT-P instrument scores
Fig. 1 – Left: Scatterplot for observed vs. predicted utility index values for the group-speciﬁc model 3. Marginal histograms of
the observed and predicted utilities are placed on the sides. The diagonal line indicates perfect agreement. Right: A Bland-
Altman plot shows the average of observed and predicted values vs. the difference between them. The dashed lines show the
95% conﬁdence agreement band.
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distribution. We considered that patients with a FACT-P instru-
ment total score of lower than 76 indicated a poor health state.
The cutoff selection was based on examining the percentage of
patients with level “3” answers on the EQ-5D questionnaire
domain scores.
For all three models, truncation was performed for predicted
values exceeding the lower or upper value (0.594 and 1, respec-
tively). There was no particular pattern in the observed utility
covariance matrix justifying a speciﬁc covariance structure such
as the autoregressive one commonly encountered in longitudinal
settings; thus, the exchangeable working covariance structure
was assumed for the models. The GEE is a robust method
regarding the covariance structure and provides consistent and
asymptotically normal solutions for the model’s coefﬁcients even
when the covariance structure is misspeciﬁed [24].
Model Selection and Cross-Validation
The suitability of each ﬁtted model was assessed by the RMSE
and the mean absolute error (MAE), both quantifying the differ-
ence between the observed and predicted values. We examined
both full and restricted models by excluding variables that were
not signiﬁcant at the 0.05 level. Furthermore, the variance
explained by the model was assessed by the marginal R2 [25].
The percentage of truncated values over the number of predicted
values was calculated for each model ﬁtted.
The selected model was ﬁtted to the full data set and cross-
validated by using a 10-fold in-sample cross-validation. Optimally,
an external data set should be used to validate the model ﬁt, but in
the absence of this, an in-sample cross-validation is the second-
best choice. The study sample was randomly split into 10 equally
sized groups. Each group was used as a validation data set, and the
remaining 90% of the data were used to develop the model. The
developed model was used on the validation data to predict the
EQ-5D questionnaire values, which were then compared with the
observed ones. The RMSE and the marginal R2 were also calculatedfor all development and estimation samples. Their values were
compared with the ones of the selected model ﬁtted on the full
data. Similarity between the 10 values was expected.
Finally, the predicted values were also compared with the
observed ones on the estimation sample by means of descriptive
statistics. To determine whether the degree of error is evenly
distributed across the scale of the EQ-5D questionnaire utility
index, the mean and predicted means were also reported for
subsets such as EQ-5Do 0, 0r EQ-5Do 0.25, 0.25r EQ-5Do 0.5,
0.5 r EQ-5D o 0.75, and 0.75 r EQ-5D r 1.
All models were ﬁtted by using the SAS software version 9.2.Results
Sample Characteristics
The number of patients with mCRPC in the estimation sample,
that is, with both FACT-P instrument and EQ-5D questionnaire
nonmissing scores simultaneously at one or more time points
during the study, was 236 patients. Demographic and baseline
characteristics for the estimation sample are presented in
Table 1, and baseline descriptive statistics for the FACT-P instru-
ment and EQ-5D questionnaire scores are presented in Table 2.
Mean FACT-P instrument domain and total scores in this sample
are in line with similar studies on prostate cancer [2]. Full
descriptive statistics for all scores and time points are shown in
Table 1 in the Supplemental Material found at http://dx.doi.org/
10.1016/j.jval.2013.12.005.
Model Selection
Models were compared on the basis of the smallest RMSE, MAE,
and highest marginal R2. Results are shown in Table 3 for all
models after truncation.
The group-speciﬁc model including the FACT-P subscale
scores and baseline variables had the best predictive performance
Table 1 – Demographic and baseline characteristics
for the estimation sample.
Characteristic Estimation sample
(N ¼ 236)
Age (y), mean  SD 68.8  7.6
Weight (kg), mean  SD 82.5  14.3
ECOG, n (%)*
0–1 222 (94.1)
2 14 (5.9)
Number of previous chemotherapies,
n (%)
1 180 (76.3)
Z2 56 (23.7)
Time (mo) from initial diagnosis of
prostate cancer to randomization,
mean  SD
78.7  48.2
Pain average score†, n (%)
o4 178 (75.4)
Z4 58 (24.6)
Fatigue severity assessment‡§, n (%)
0 88 (41.9)
Z1 122 (58.1)
ECOG, Eastern Cooperative Oncology Group.
 N ¼ 234.
† Average pain score as assessed by Brief Pain Inventory — Short
Form Question no. 3 during the week before randomization.
‡ N ¼ 210.
§ Fatigue severity assessment according to the National Cancer
Institute Common Terminology Criteria for Adverse Events 4.0
criteria.
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the good health group and the PWB and EWB subscales in the
poor health group had the highest explanatory value. The GEE on
the total estimation sample and the TPM including the FACT-P
instrument subdomain scores and baseline variables also had
good predictive performance (see Table 3). Cross-validation gave
similar index values for all 10 samples (results not shown).
Coefﬁcients for the group-speciﬁc model are given in Table 4,
and a scatterplot of the observed compared with the predicted
utility values is shown in Figure 1 (left panel). A Bland-Altman
plot of the average observed and predicted utilities versus their
difference is also provided in Figure 1 (right panel). The 95%
agreement band embraces approximately 95% of the values
indicating a good agreement. Coefﬁcients and a scatter plot ofTable 2 – Quality-of-life baseline descriptive statistics fo
Theoretical range N Mean  SD
FACT-P
Physical WB (0–28) 208 21.1  5.6
Social/Family WB (0–28) 201 17.0  6.1
Emotional WB (0–24) 203 16.8  4.6
Functional WB (0–28) 207 21.5  5.0
Prostate Cancer
Subscale (0–48) 206 30.2  7.7
Total score (0–156) 198 106.4  21.9
EQ-5D questionnaire
Utility index (0.594 to 1) 209 0.688  0.28
EQ-5D, EuroQol ﬁve-dimensional; FACT-P, Functional Assessment of Canthe observed versus predicted utility values for the other two
models are shown in the Supplemental Material found at http://
dx.doi.org/10.1016/j.jval.2013.12.005.
To assess whether the degree of error is evenly distributed
across the full range of EQ-5D questionnaire values, we compared
the mean error, MAE, and RMSE by subsets of the total range.
Table 5 shows these indices for the overall distribution and for
different subsets separately. Overall the mean utility index is
accurately estimated as the low mean error indicates; neverthe-
less, there is overprediction for utility values under 0.5, which
correspond to patients with “extreme problems” on at least one of
the ﬁve EQ-5D questionnaire dimensions (poor health) and slight
underprediction for the higher utility values (good health). This
tendency is commonly observed in similar studies [16,22,23,26] and
is because the models ﬁtted are aiming to model the mean utility
rather than the whole distribution of non-normal utility values.Discussion
In the absence of a preference-based outcome measure, a statistical
model that maps the HRQOL measures commonly collected in
prostate cancer clinical studies to utility values could prove useful.
The estimation of these missing health-related utility data enables
the calculation of quality-adjusted life-year and the analysis of cost-
utility. Barton et al. [27] found that there were differences in quality-
adjusted life-year gains when using observed or predicted by
mapping utility values and encouraged the actual collection of
preference-based measures, although they admit that their results
may not be generalizable. NICE recommends the use of mapping
techniques in the absence of directly collected preference-based
outcome measures; however, the use of these techniques would
lead to increased uncertainty around utility estimates and they
should be considered a second-best solution [28]. We have estimated
an algorithm to map to the EQ-5D questionnaire from the FACT-P
instrument by using data from a sample of patients with prostate
cancer. This analysis has demonstrated a method of incorporating
data from repeated observations with good statistical properties.
Models published in the literature have mainly been based on
linear regression using OLS. This is not adequate in prospective
studies because it does not take into account the correlation
between repeated measurements. Some authors have opted for
using only the baseline data to estimate the OLS regression, and
then use this to predict values at future time points [4,14]. It has
been discussed that a longitudinal study could provide evidence
on the relationship of the changes of both instruments [9]. Given
the fact that methods such as the GEE are now standard, we
decided to use all available data under a longitudinal framework.r the estimation sample.
Median Min Max % Floor % Ceiling
22.2 4 28 0.0 8.17
17 0 28 0.5 3.48
18 5 24 0.0 1.97
22.2 0 28 1.45 7.73
31 2.7 45 0.0 0.0
108.5 54.8 147.6 0.0 0.0
2 0.727 0.59 1 0.48 20.1
cer Therapy–Prostate; WB, well-being.
Table 3 – Performance indexes for the different mapping algorithms.
Model* Marginal R2 RMSE MAE Truncation percentage (at value 1)
GEE
Model 1 0.671 0.176 0.128 5.75
Model 2 0.658 0.179 0.131 4.57
Model 3 0.691 0.170 0.124 4.36
Model 4 0.595 0.185 0.133 3.37
Two-part model
Model 1 0.671 0.175 0.129 0.45
Model 2 0.580 0.189 0.138 1.33
Model 3 0.693 0.169 0.124 0.11
Model 4 0.592 0.186 0.135 0.00
Group-speciﬁc model
Model 1 0.701 0.167 0.121 2.71
Model 2 0.668 0.175 0.126 1.70
Model 3 0.718 0.162 0.117 2.25
Model 4 0.608 0.181 0.128 0.91
FACT-P, Functional Assessment of Cancer Therapy–Prostate; GEE, generalized estimating equations; MAE, mean absolute error; RMSE, root
mean squared error.
 Models correspond to: Model 1: Full model using the overall FACT-P score; Model 2: Restricted model using the overall FACT-P score; Model 3:
Full model using individual components of the FACT-P instrument; and Model 4: Restricted model using individual components of the FACT-
P instrument.
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representing full health, and data obtained from the EQ-5D
questionnaire usually exhibit a ceiling effect (e.g., percentage of
perfect health in the estimation sample was 22% across all visits).
We accommodated this by ﬁtting a TPM, the ﬁrst part of which is
modeling the probability of presenting full health and the second
a standard GEE to predict values of less than 1. A ﬂoor effect was
not a concern in our data set (percentage of worst utility value
was 0.5% across all visits). This reduced the amount of truncation
needed. Furthermore, we investigated the adequacy of ﬁtting two
separate GEE models for patients with poor and good health to
deal with over- and underprediction observed in other studies
and in the ﬁrst two techniques. Mapping to the individual EQ-5D
questionnaire domains could provide additional information at
an item level, but was not considered for this data set because
there were very few observations with the most severe level for
each domain to provide an adequate ﬁt to a multinomial logistic
regression model (percentages of the most severe level for eachTable 4 – Coefﬁcients for the group-speciﬁc model with F
Model/variables Poor health
Coefﬁcient
Intercept 0.2343
ECOG at baseline (0–1 vs. 2) 0.2225
Number of previous chemotherapy regimens (1 vs. Z2) 0.0700
Age 0.0095
Weight 0.0023
Baseline average pain score (o4 vs. Z4) 0.1125
Fatigue severity (no fatigue vs. fatigue) 0.1416
Physical WB 0.0277
Social/Family WB 0.0006
Emotional WB 0.0214
Functional WB 0.0160
PCS 0.0124
ECOG, Eastern Cooperative Oncology Group; FACT-P, Functional Assessm
standard error; WB, well-being.domain were 1.23% for mobility, 1.54% for self-care, 6.31% for
usual activities, 6.63% for pain/discomfort, and 3.85% for anxiety/
depression).
The models developed in this article had a good predictive
ability, with RMSE between 0.162 and 0.170, MAE between 0.117
and 0.124, and a marginal R2 between 0.691 and 0.718. Brazier et al.
[22] in their systematic review of mapping studies reported one of
the best models in terms of performance as one with an R2 of 0.51
and a range of 0.17 to 0.71. The authors also reported a range for
RMSE from 0.084 to 0.2 and for MAE from 0.0011 to 0.19 in the
studies included in the review. This review also identiﬁed a
similar study that mapped the FACT-P instrument scores to EQ-
5D questionnaire utility values in a prostate cancer population [2].
Only baseline values were used to develop the algorithm for this
study, and OLS and median regression models were used. The
selected model in this study explained 58.2% of the variability in
EQ-5D questionnaire observed values and had an MAE of 0.146. As
in other oncology studies in which the FACT-G instrument or theACT-P subdomains as covariates.
(FACT-P scoreo 76) Good health (FACT-P score Z 76)
s SE P Coefﬁcients SE P
0.5003 0.6396 0.3475 0.2229 0.1191
0.1104 0.0438 0.0839 0.0823 0.3082
0.1135 0.5377 0.0087 0.0198 0.6602
0.0055 0.0876 0.0025 0.0016 0.1115
0.0025 0.3447 0.0015 0.0009 0.0734
0.0741 0.1287 0.0568 0.0282 0.0438
0.1104 0.1996 0.0291 0.0183 0.1108
0.0091 0.0022 0.0111 0.0036 0.0021
0.0091 0.9442 0.0006 0.0019 0.7362
0.0113 0.0577 0.0089 0.0031 0.0037
0.0104 0.1247 0.0048 0.0024 0.0452
0.0077 0.1073 0.0060 0.0018 0.0008
ent of Cancer Therapy–Prostate; PCS, prostate cancer subscale; SE,
Table 5 – Mean error, mean absolute error, and root mean squared error of predicted compared with observed utility values for GEE, TPM, and GSM.
EQ-5D questionnaire utilityindex* range GEE1 GEE2 GEE3 GEE4 TPM1 TPM2 TPM3 TPM4 GSM1 GSM2 GSM3 GSM4
Mean error
Full range 0.004 0.004 0.002 0.002 0.004 0.004 0.002 0.002 0.005 0.005 0.004 0.004
r0 0.479 0.489 0.450 0.492 0.474 0.503 0.456 0.495 0.335 0.372 0.317 0.422
(0–0.25) 0.271 0.293 0.260 0.260 0.265 0.266 0.258 0.260 0.238 0.225 0.235 0.225
(0.25–0.50) 0.216 0.212 0.211 0.199 0.207 0.186 0.195 0.183 0.249 0.244 0.236 0.248
(0.50–0.75) 0.030 0.033 0.035 0.040 0.030 0.036 0.039 0.041 0.014 0.022 0.020 0.030
(0.75–1.00) 0.054 0.056 0.044 0.053 0.054 0.061 0.041 0.051 0.058 0.059 0.050 0.059
Mean absolute error
Full range 0.128 0.131 0.124 0.133 0.129 0.138 0.124 0.135 0.121 0.126 0.117 0.128
r0 0.479 0.489 0.450 0.492 0.474 0.503 0.456 0.495 0.353 0.373 0.336 0.422
(0–0.25) 0.278 0.293 0.269 0.264 0.277 0.273 0.266 0.263 0.280 0.273 0.264 0.248
(0.25–0.50) 0.227 0.219 0.222 0.207 0.221 0.198 0.211 0.193 0.258 0.273 0.255 0.282
(0.50–0.75) 0.105 0.105 0.106 0.111 0.108 0.112 0.109 0.116 0.097 0.102 0.097 0.105
(0.75–1.00) 0.104 0.107 0.097 0.103 0.104 0.111 0.095 0.104 0.100 0.101 0.096 0.101
Root mean squared error
Full range 0.176 0.179 0.170 0.185 0.175 0.189 0.169 0.186 0.167 0.175 0.162 0.181
r0 0.200 0.218 0.217 0.240 0.208 0.223 0.218 0.236 0.276 0.250 0.277 0.255
(0–0.25) 0.153 0.148 0.163 0.156 0.156 0.155 0.154 0.148 0.222 0.233 0.210 0.205
(0.25–0.50) 0.134 0.126 0.135 0.124 0.142 0.132 0.139 0.133 0.144 0.165 0.149 0.177
(0.50–0.75) 0.127 0.126 0.130 0.133 0.129 0.134 0.131 0.138 0.129 0.138 0.129 0.140
(0.75–1.00) 0.125 0.126 0.116 0.124 0.125 0.131 0.116 0.124 0.112 0.111 0.109 0.112
EQ-5D, EuroQol ﬁve-dimensional; FACT-P, Functional Assessment of Cancer Therapy–Prostate; GEE, generalized estimating equations; GSM, group-speciﬁc model; TPM, two-part model.
 The index numbers 1 to 4 correspond to the four models ﬁtted with each method (Model 1: Full model using the overall FACT-P score; Model 2: Restricted model using the overall FACT-P
score; Model 3: Full model using individual components of the FACT-P instrument; and Model 4: Restricted model using individual components of the FACT-P instrument).
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instrument is mapped to the EQ-5D questionnaire, we found that
the Social/Family Well-being domain did not signiﬁcantly affect
the EQ-5D questionnaire score.
The methods used were not free of limitations. The GEE
models the mean of the response variable, which obliges the
means of the observed and predicted values to be similar and
could possibly conceal a misﬁt in the lower or upper end of the
data distribution. This is especially true when dealing with highly
skewed data with a ceiling effect, such as the EQ-5D questionnaire
data, whose distribution is far from normal. The general ﬁt though
is rather satisfactory with R2 higher than in previous studies
found in the literature and RMSE and MAE within the range seen
in previous studies [22]. One way to avoid this is to predict a mean
cohort EQ-5D questionnaire utility index directly by using the
mean score of the disease-speciﬁc instrument instead of the
individual subject predictions, as in Ara and Brazier [17].
The group-speciﬁc model was ﬁtted to decrease the prediction
error in the lower and upper end of the distribution compared
with the GEE model (total cohort) and the TPMs. The results
presented by the EQ-5D questionnaire range showed that
although providing a reduction in the MAE for the lower range,
there was no improvement in the RMSE. This is due to a small
number of predictions at the very end of the scale with high errors
(see Fig. 1, left panel). In applying the algorithm, it is important to
consider the likely proportion of patients at the severe end of the
scale where the error in the prediction is greater. The proportion
of patients with utility values lower than 0.5 was modest (12.9% in
the estimation sample). We have not been able to identify studies
onmCRPC in which the EQ-5D questionnaire values were reported
by the range, but because our baseline mean EQ-5D questionnaire
value of 0.688 is within the range of average utility values reported
in other studies [2,29–31], we do not expect the sample to be
atypical of patients with mCRPC.
Mapping algorithms have proven to be useful alternatives in
the absence of EQ-5D questionnaire data collection in studies in
which economic evaluations are to follow. Our results conﬁrm
that utility values can be predicted when data on an HRQOL non–
preference-based instrument are collected.
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